Javier Fernández-Ruiz Selected Research

Javier Fernández-Ruiz Research Topics

Disease

28	Parkinson Disease (Parkinson's Disease) 12/2021 - 06/2005
23	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021 - 05/2003
22	Huntington Disease (Huntington's Disease) 01/2019 - 04/2002
13	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2021 - 12/2007
11	Disease Progression 01/2021 - 10/2004
9	Multiple Sclerosis 01/2016 - 11/2005
8	Inflammation (Inflammations) 10/2023 - 01/2016
6	Basal Ganglia Diseases (Basal Ganglia Disease) 01/2019 - 01/2006
6	Tremor (Tremors) 06/2012 - 05/2004
5	Gliosis 05/2023 - 10/2006
5	Alzheimer Disease (Alzheimer's Disease) 03/2021 - 04/2009
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2015 - 11/2005
5	Hypokinesia (Bradykinesia) 12/2009 - 05/2004
4	Myoclonic Epilepsies (Myoclonic Encephalopathy) 10/2023 - 01/2016
4	Atrophy 01/2021 - 01/2006
4	Ataxia (Dyssynergia) 01/2017 - 08/2006
4	Pain (Aches) 11/2015 - 11/2005
3	Frontotemporal Dementia (Semantic Dementia) 03/2024 - 06/2015
3	Seizures (Absence Seizure) 01/2022 - 01/2016
3	Nervous System Diseases (Neurological Disorders) 01/2020 - 01/2006
3	Substance-Related Disorders (Drug Abuse) 01/2019 - 06/2003
3	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2019 - 12/2016
3	Hyperkinesis 07/2005 - 04/2002
2	Brain Diseases (Brain Disorder) 10/2023 - 04/2009
2	Febrile Seizures (Febrile Seizure) 01/2022 - 01/2020
2	Paralysis (Palsy) 01/2021 - 06/2015
2	Epileptic Syndromes 01/2020 - 01/2016
2	Dyskinesias (Dyskinesia) 01/2020 - 01/2006
2	Neuroinflammatory Diseases 07/2019 - 02/2013
2	Fibrosis (Cirrhosis) 10/2018 - 02/2016
2	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2018 - 02/2012
2	Alcoholism (Alcohol Abuse) 11/2015 - 07/2015
2	Motor Disorders 03/2014 - 08/2002
2	Vomiting 02/2013 - 05/2012
2	Schizophrenia (Dementia Praecox) 02/2013 - 06/2010
2	Nausea 02/2013 - 05/2012
2	Parkinsonian Disorders (Parkinsonism) 06/2011 - 02/2006
2	Autoimmune Diseases (Autoimmune Disease) 08/2006 - 11/2005
1	Glucose Intolerance 01/2021
1	Hyperglycemia 01/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021
1	Experimental Arthritis 01/2020

Drug/Important Bio-Agent (IBA)

49	CannabinoidsIBA 03/2024 - 04/2002
32	EndocannabinoidsIBA 03/2024 - 04/2002
13	CannabidiolIBA 10/2023 - 02/2007
12	Neuroprotective AgentsIBA 03/2024 - 05/2003
9	CB2 Cannabinoid ReceptorIBA 03/2024 - 04/2008
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 07/2010
7	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2021 - 10/2004
7	EnzymesIBA 01/2018 - 04/2002
6	cannabigerolIBA 05/2021 - 01/2016
6	AntioxidantsIBA 01/2020 - 02/2007
6	nabiximols (Sativex)IBA 03/2017 - 09/2011
5	quinone (benzoquinone)IBA 05/2021 - 03/2015
5	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2020 - 02/2006
5	Cannabinoid Receptor AgonistsIBA 02/2014 - 05/2003
4	LigandsIBA 03/2024 - 11/2005
4	anandamide (arachidonylethanolamide)IBA 05/2023 - 05/2004
4	Glutamic Acid (Glutamate)FDA Link 11/2018 - 05/2008
4	malonic acid (malonate)IBA 05/2012 - 05/2003
4	Dopamine (Intropin)FDA LinkGeneric 06/2011 - 04/2002
4	RimonabantIBA 05/2008 - 05/2003
4	3-nitropropionic acidIBA 08/2007 - 11/2002
3	CytokinesIBA 01/2021 - 06/2011
3	gamma-Aminobutyric Acid (GABA)IBA 06/2010 - 04/2002
2	caryophylleneIBA 10/2023 - 01/2022
2	Sodium Channels (Sodium Channel)IBA 01/2022 - 01/2020
2	Oxidopamine (6 Hydroxydopamine)IBA 05/2021 - 06/2005
2	Calcium Gluconate (CBG)IBA 01/2021 - 07/2019
2	Levodopa (L Dopa)FDA LinkGeneric 01/2020 - 01/2006
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 07/2019 - 05/2012
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 07/2019 - 01/2016
2	LipopolysaccharidesIBA 07/2019 - 01/2016
2	Bleomycin (Blenoxane)FDA LinkGeneric 10/2018 - 02/2016
2	Antineoplastic Agents (Antineoplastics)IBA 03/2015 - 01/2013
2	Transcription Factors (Transcription Factor)IBA 06/2011 - 07/2010
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 07/2010 - 10/2006
2	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 07/2010 - 04/2002
2	alpha-SynucleinIBA 07/2010 - 01/2009
2	ElementsIBA 01/2009 - 04/2008
2	arvanilIBA 10/2006 - 07/2005
2	N- (2- methyl- 3- hydroxyphenyl)- 5,8,11,14- eicosatetraenamideIBA 10/2006 - 03/2003
2	AmidesIBA 10/2006 - 07/2005
2	N- (3- furylmethyl)eicosa- 5,8,11,14- tetraenamideIBA 10/2006 - 01/2006
2	N-(4-hydroxyphenyl)arachidonylamide (AM404)IBA 10/2006 - 03/2003
1	CatalaseIBA 10/2023
1	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 05/2023
1	NeurotoxinsIBA 12/2021
1	Endoplasmic Reticulum Chaperone BiPIBA 11/2021
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 03/2021
1	SaltsIBA 01/2021
1	CreatinineIBA 01/2021
1	Streptozocin (Streptozotocin)FDA Link 01/2021
1	Nuclear Proteins (Protein, Nuclear)IBA 10/2020
1	DNA-Binding Proteins (DNA Binding Protein)IBA 10/2020
1	Pentylenetetrazole (Metrazol)IBA 01/2020
1	AcidsIBA 01/2020

Therapy/Procedure

15	Therapeutics 03/2024 - 12/2009
4	Injections 07/2019 - 11/2002
2	Muscle Denervation 01/2021 - 06/2015